Skin cancer is currently the most frequent type of cancer. At present, life time risk is estimated at 1 in 6 and with the aging of the population this is expected to increase even more. It is assumed that early detection gives better cure rates and more cost-effective treatment. Therefore, skin cancer seems particulary amenable to screening initiatives. However, questions remain about their cost benefit.
First of all, this study aims at calculation the actual cost of skin cancer in Belgium, and the expected cost with an aging population. We will also estimate how much early detection of skin cancer could affect cost.